Stavudine adverse reactions: Difference between revisions

Jump to navigation Jump to search
Ahmed Zaghw (talk | contribs)
No edit summary
Ahmed Zaghw (talk | contribs)
 
(2 intermediate revisions by the same user not shown)
Line 7: Line 7:
The following adverse reactions are discussed in greater detail in other sections of the labeling:
The following adverse reactions are discussed in greater detail in other sections of the labeling:


*:[[lactic acidosis]] and severe [[hepatomegaly]] with steatosis
*:[[Lactic acidosis]] and severe [[hepatomegaly]] with steatosis
*:[[Hepatic toxicity]]
 
*:Hepatic injury
 
*:Neurologic symptoms and motor weakness  
*:Neurologic symptoms and motor weakness  
*:[[Pancreatitis]]  
*:[[Pancreatitis]]  
*:[[lipoatrophy]]/[[lipodystrophy]]
*:[[lipoatrophy]]/[[lipodystrophy]]



Latest revision as of 07:14, 3 January 2014

Stavudine
Zerit® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Adverse Reactions

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Hepatic injury
  • Neurologic symptoms and motor weakness

When ZERIT is used in combination with other agents with similar toxicities, the incidence of adverse reactions may be higher than when stavudine is used alone.[1]

References

  1. "ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) POWDER, FOR SOLUTION [E.R. SQUIBB & SONS, L.L.C.]".

Adapted from the FDA Package Insert.